MediPharm Labs Corp.
LABS.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 19.27% | 26.62% | 32.77% | 48.31% | 58.07% |
| Total Depreciation and Amortization | 1.95% | 16.82% | 13.71% | 8.05% | -15.90% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 130.29% | 157.53% | 143.20% | -196.76% | -205.02% |
| Change in Net Operating Assets | -52.65% | -7.69% | -30.31% | -45.35% | -45.48% |
| Cash from Operations | 61.32% | 83.57% | 64.39% | 22.46% | 26.89% |
| Capital Expenditure | 67.94% | 65.66% | 37.24% | 38.28% | 46.78% |
| Sale of Property, Plant, and Equipment | -72.88% | -61.16% | -- | 35,438.18% | 28,074.55% |
| Cash Acquisitions | -- | -100.00% | -100.00% | -- | -- |
| Divestitures | -- | -29.51% | -29.51% | -29.51% | -29.51% |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -93.93% | -42.65% | 2.34% | 41.58% | 34.35% |
| Total Debt Issued | -25.12% | -25.12% | -29.80% | -20.43% | -20.43% |
| Total Debt Repaid | -51.72% | -43.88% | 41.33% | -43.35% | -112.13% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -32.12% | -18.23% | -12.95% | 961.07% | 42.93% |
| Cash from Financing | -405.53% | -252.49% | 119.04% | 1,612.92% | -141.50% |
| Foreign Exchange rate Adjustments | 101.58% | -73.61% | -179.00% | -224.92% | -293.24% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 0.53% | 102.19% | 116.39% | 61.56% | 42.42% |